Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Li, Wen-Qian, Li, Ling-Yu, Bai, Ri-Lan, Qian, Lei, Chen, Nai-Fei, Cui, Jiu-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722558/
https://www.ncbi.nlm.nih.gov/pubmed/33009031
http://dx.doi.org/10.1097/CM9.0000000000001120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722558/
https://www.ncbi.nlm.nih.gov/pubmed/33009031
http://dx.doi.org/10.1097/CM9.0000000000001120

Ejemplares similares